Summary Radioimmunotherapy (RIT) is currently limited by toxicity to normal tissues as a result of prolonged circulating radioantibody in the blood. In this study, the use of a cleanng antibody was investigated (second antibody) in an attempt to reduce blood background levels of [9Y]A5B7 immunoglobulin G (IgG) activity, and, therefore, improve the therapeutic tumour-blood ratio in nude mice bearing human colorectal tumour xenografts. The second antibody was raised against the 1 2N4 macrocycle group used for chelation of 90Y. and is, thus, applicable to any anti-tumour antibody labelled with this methodology. Second antibody was administered 18, 24 or 48 h after radiolabelled antibody injection and produced up to a tenfold reduction in blood levels and a tenfold improvement in tumour-blood ratios. This has the advantage of reducing the risk of myelotoxicity caused by prolonged retention of activity in the blood. For all normal tissues, there was a similar or slightly lower uptake of [90Y]lgG with second antibody clearance, apart from a transient rise in liver activity due to complexes of primary and secondary antibody clearing via the liver. As a result of clearance of [90Y]lgG from the blood pool, there was an associated fall in the amount of antibody at the tumour site (up to 3.3-fold) at later time points for mice injected with second antibody. However, despite this, tumour-blood ratios remained superior to the control group at these later time points. Estimated dosimetry evaluation revealed that total dose to normal tissues, blood and tumour was lower than for the non-clearance group. Surprisingly, however, there was little improvement in total estimated tumour-blood dose ratio over the time period studied. This was probably because the majority of the dose was delivered to both the blood and tumour within the first 24 h after administration of [90Y]lgG, so that giving the clearing agent after this time did not produce a large difference in total estimated dose. The anti-macrocycle second antibody proved to be a successful clearing agent and could potentially be applied to any anti-tumour antibody coupled with the 12N4 macrocycle. In the light of the estimated dosimetry results described here, it would probably be most useful given at earlier time points (i.e. before 18 h after injection of primary antibody) to produce an improved tumour-blood ratio of total dose. Development of this strategy may allow higher levels of activity to be administered for RIT, and repeated dosing regimens.
tissues. The slow clearance of intact radiolabelled antibodies from the circulation and the time necessarv to achieve maximum uptake by the tumour has often resulted in large radiation doses to normal tissues. The amount of radiation that mav be administered for RIT is often limited by the potential damage to normal tissues. especially the bone marrow. caused by the persistence of radiolabelled antibodv in the circulation. Sexeral strategies hax-e been employed in an attempt to remove circulating antibody more rapidly. and produce high tumour-blood (therapeutic) ratios. These include the use of smaller. faster. clearing antibody fragments (Buchegger et al. 1990 : Pedley et al. 1993 . and specific in x-ivo or ex vivo clearing regimes (Begent et al. 1987 : Norrgren et al. 1993 .
Prev-ious studies haxe demonstrated successful implementation of clearing acents. The use of a second antibody directed against the ( pnmary ) anti-tumour antibody has accelerated clearance and improved therapeutic ratios (Begent et al. 1987 : Pedley et al. 1989 . Other strategies have involved liposomally entrapped second antibodies (Keep et al. 1983 ) and axvidin-biotin systems (Marshall et al. 1995) .
Most therapeutic studies to date haxe been carried out using the radionuclide iodine-131 (1""I). xhich is a medium range 3-emitter (0.6 MeV). However. there are problems associated with handlin2 large doses of ""I for RIT because of the high abundance of yenergy. More recently. sex eral inx estigators have suggested that alternative radionuclides such as yttrium-90 COY) or copper-67 C6-Cu) may be superior to ""I for RIT (Deshpande et al. 1988 : King et al. 1994 . Faxourable characteristics include higherenergy. shorter physical half-lives and stable chelation methods.
Several studies hax e also reported higher tumour uptake and prolonged retention of 5'Y in tumour cells compared with I'l. e.g. Press et al (1996) .
The murine antibodv A5B7. raised against carcinoembrxonic antigen (CEA). has been used for RIT labelled w-ith "I in nude mice bearing human colorectal tumour xenografts (Pedley et al. 1993 ) and in patients with colorectal cancer (Lane et al. 1994 ).
Good therapeutic responses haxe been demonstrated in xenograft models. but only a small number of responses hax e been produced clinicallI. In a recent studv. the 12N4 DOTA macrocvcle was conjugyated to A5B7 IgG and sucessfully radiolabelled wxith 41Y. 1307 The biodistribution of A5B7 IgG radiolabelled %vith either '"'I or 9'Y in the nude mouse xenograft model was compared and the results show ed that higher tumour uptake and retention of
[3VY]IgG was observed (Casey et al. 1996) . The aim in this studv was to investigate whether tumour-blood ratios could be further improved for [VY] IgG using a second antibody clearance system based on an antibodv raised against the 1 2N4 DOTA macrocycle.
MATERIALS AND METHODS

Antibodies
The 12N4 DOTA macrocvcle %vas conjugated to bovine serum albumin for immunizations. usinc the method previouslI described by Turner et al ( 1994) . Clearance at 18 h produced a significant decrease (P < 0.05) in blood activity (6.2-and 6.6-fold) measured 24 and 48 h after administration ( Figure 2B and C) . In contrast to administration of clearinc agent at 24 h (Figure 1 ). tumour uptake lexels were significantl1
British Joumal of Cancer (1998) Figure 2A) . by which time blood levels have declined naturally and there would be little advantage in administering a clearing agent at this time. In previous studies. clearing agents have generally been administered 24-48 h after injection of pnmarv antibody. which is usually at the approximate peak level of tumour localization (Begent et al. 1987 : Marshall et al. 1994 ). These studies have also reported improved tumour-blood ratios.
It is. however. important to consider not only the biodistribution data at various time points after clearance. but also area under the curve analysis of total dose when considering the potential merit of second antibody clearance. Although these dosimetry calculations can only be considered as estimates. they have previously proved useful predictors of toxicity and a guide to the levels of activitv that may be administered for RIT (Pedley et al. 1989 (Pedley et al. . 1993 . Surprisingly. although blood activity was significantly reduced after second antibody administration this only had a small effect on the cumulative radiation dose. most of which had already been given before injection of second antibody (i.e. before 24 h). Thus. these dosimetry estimates predicted no overall improvement in the tumour-blood dose ratio. Without considering these calculations. it would appear that the higher tumour-blood ratios observed at specific time points after clearance from the biodistribution data provide an advantage in terms of lower toxicitv.
The beneficial effect of second antibody clearance was observed in the first 24 h after administration of clearing agent. when a tenfold reduction in total dose to the blood occurred. However. this was not reflected in the overall dose estimates because the majority of the total dose to blood and tumour had occurred before the clearing antibody was administered. Even at the earliest second antibody clearance time point ( 18 h These studies were performed using ''"I-labelled antibodies compared with 9"Y used in this study. which may explain the discrepancy. 90Y is a higher energy [emitter. which will deliver a higher initial dose rate to the tumour than ''I. This results in the relatively high absorbed dose during the first 24 h after administration. If the anti-macrocycle clearing antibodvsAas administered at 6 h. then it is possible that an improved cumulative tumour-blood ratio could be generated. which may allow a larger amount of activity to be administered. In addition. this will produce a higher initial dose rate to the tumour which is known to be an important parameter for successful RIT (Fowler. 1990 ). Furthermore. this therapeutic strategy. which should ultimately reduce myelotoxicitv by the early removal of radiolabelled primary antibody. would favour repeated doses that could be administered at relatively frequent intervals. There are. however. two possible disadvantages to this therapeutic strategry. The immunogenicity of both murine antibodies and the high levels of administered activity. and therefore protein.
required for therapy that may result in a large amount of immune complex formation. which could saturate the reticuloendothelial system and lead to the circulation of excess immune complexes.
Technoloay is now available to produce humanized antibodies.
and there is evidence to suggrest that the immune response for the limited number of humanized antibodies used clinically so far is largely reduced (Juweid et al.. 1995 : Sharkey et al.. 1995 : Stephens et al.. 1995 . The liver receives the highest normal tissue absorbed dose with second antibody clearance. and. therefore. careful attention to possible hepatic toxicity and clearance of circulating immune complexes is required in a dose escalation manner if this strategy is to be used cliically.
This clearance strategy is of great interest because of its potential universal application to any anti-tumour antibody. Conjugation of the 12N4 macrocycle is a mild procedure and does not generally affect the immunoreactivit-v. This labelling procedure has also been applied to cross-linked antibody fragments (Casey et al.. 1996) . If used in combination with a metallic isotope such as indium-11 1 and the anti-macrocycle antibody. this may be advantageous for radioimmunodetection because improved images could be generated at earlier time points.
British Joumal of Cancer (1998) The purpose of giving second antibodv >-as to investigate whether the radiation dose to bone marrow-could be reduced. permitting a higher tumour dose to be delivered. Although blood activity w-as sinificantlv reduced after second antibody administration (given at 18. 23 or 47 h after primary antibodv). this onl1 had a small effect on the cumulative radiation dose. most of which had been iyven before second antibody administration. If second antibody was administered at an earlier time (e.g. 6 h after primary antibod ). it is possible that the usefulness of this system could be improved by the deliver-of a higher initial dose rate to the tumour to achieve a oreater cell kill. Further experiments are required to optimize this potentially new therapeutic strategy.
